After disastrous Galapagos deal, Gilead finds new rheumatoid arthritis partner

Gilead is looking for another shot at treating rheumatoid arthritis after its massive Galapagos deal fell flat in the face of an FDA rejection and, more recently, a withdrawn Phase I of another asset for the inflammatory disease.

The California biopharma, coming off a strong finish to 2022 with an...

Click to view original post